Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-α and C-raf kinase
- Author
- HENRY, S. P1 ; MONTEITH, D1 ; BENNETT, F1 ; LEVIN, A. A1
[1] Isis Pharmaceuticals, Inc., 2292 Faraday Avenue, Carlsbad, CA 92008, United States - Source
Anti-cancer drug design. 1997, Vol 12, Num 5, pp 409-420 ; ref : 2 p.1/4
- ISSN
- 0266-9536
- Scientific domain
- Medical oncology; Pharmacology drugs
- Publisher
- Oxford University Press, Oxford
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Keyword (fr)
- Animal Anticancéreux Article synthèse Cinétique Distribution Dose forte Dose répétée Ether Gène onc cellulaire Hybridation Immunostimulation Inhibiteur enzyme Isozyme Oligonucléotide antisens Pharmacocinétique Produit gène Protein kinase C Résistance hydrolyse Souris Stabilité Système immunitaire Séquence nucléotide Thiophosphate organique Tissu Toxicité Toxicocinétique Voie intraveineuse Cytosine(5-méthyl) ISIS 1082 ISIS 12854 ISIS 13108 ISIS 13650 Protéine raf Enzyme Hémopathie Immunopathologie Mammalia Rodentia Transferases Vertebrata
- Keyword (en)
- Animal Antineoplastic agent Review Kinetics Distribution High dose Multiple dose Ether C-Onc gene Hybridization Immunostimulation Enzyme inhibitor Isozyme Antisense oligonucleotide Pharmacokinetics Gene product Protein kinase C Hydrolysis resistance Mouse Stability Immune system Nucleotide sequence Organic thiophosphate Tissue Toxicity Toxicokinetics Intravenous administration Enzyme Hemopathy Immunopathology Mammalia Rodentia Transferases Vertebrata
- Keyword (es)
- Animal Anticanceroso Artículo síntesis Cinética Distribución Dosis fuerte Dosis múltiple Eter Gen onc celular Hibridación Inmunoestimulación Inhibidor enzima Isozima Oligonucleótido antisentido Farmacocinética Producto gene Protein kinase C Resistencia hidrólisis Ratón Estabilidad Sistema inmunitario Secuencia nucleótido Tiofosfato orgánico Tejido Toxicidad Toxicocinética Vía intravenosa Enzima Hemopatía Inmunopatología Mammalia Rodentia Transferases Vertebrata
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02U Drug toxicity and drugs side effects treatment / 002B02U10 Miscellaneous (drug allergy, mutagens, teratogens...)
- Discipline
- Drugs toxicity and drug intoxications Toxicology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 2743783
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Install on your browser
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:131:\"Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-\u03b1 and C-raf kinase\";s:9:\"\u0000*\u0000jtitle\";s:23:\"Anti-cancer drug design\";s:9:\"\u0000*\u0000stitle\";s:21:\"Anti-cancer drug. des\";s:7:\"\u0000*\u0000date\";s:4:\"1997\";s:9:\"\u0000*\u0000volume\";s:2:\"12\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"409\";s:8:\"\u0000*\u0000epage\";s:3:\"420\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0266-9536\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"HENRY\";s:10:\"\u0000*\u0000aufirst\";s:4:\"S. P\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:11:\"MONTEITH, D\";i:1;s:10:\"BENNETT, F\";i:2;s:11:\"LEVIN, A. A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:131:\"Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-\u03b1 and C-raf kinase\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:131:\"Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-\u03b1 and C-raf kinase\";s:9:\"\u0000*\u0000jtitle\";s:23:\"Anti-cancer drug design\";s:9:\"\u0000*\u0000stitle\";s:21:\"Anti-cancer drug. des\";s:7:\"\u0000*\u0000date\";s:4:\"1997\";s:9:\"\u0000*\u0000volume\";s:2:\"12\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"409\";s:8:\"\u0000*\u0000epage\";s:3:\"420\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0266-9536\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"HENRY\";s:10:\"\u0000*\u0000aufirst\";s:4:\"S. P\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:11:\"MONTEITH, D\";i:1;s:10:\"BENNETT, F\";i:2;s:11:\"LEVIN, A. A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:131:\"Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-\u03b1 and C-raf kinase\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:131:\"Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-\u03b1 and C-raf kinase\";s:9:\"\u0000*\u0000jtitle\";s:23:\"Anti-cancer drug design\";s:9:\"\u0000*\u0000stitle\";s:21:\"Anti-cancer drug. des\";s:7:\"\u0000*\u0000date\";s:4:\"1997\";s:9:\"\u0000*\u0000volume\";s:2:\"12\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"409\";s:8:\"\u0000*\u0000epage\";s:3:\"420\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0266-9536\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"HENRY\";s:10:\"\u0000*\u0000aufirst\";s:4:\"S. P\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:11:\"MONTEITH, D\";i:1;s:10:\"BENNETT, F\";i:2;s:11:\"LEVIN, A. A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:131:\"Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-\u03b1 and C-raf kinase\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:131:\"Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-\u03b1 and C-raf kinase\";s:9:\"\u0000*\u0000jtitle\";s:23:\"Anti-cancer drug design\";s:9:\"\u0000*\u0000stitle\";s:21:\"Anti-cancer drug. des\";s:7:\"\u0000*\u0000date\";s:4:\"1997\";s:9:\"\u0000*\u0000volume\";s:2:\"12\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"409\";s:8:\"\u0000*\u0000epage\";s:3:\"420\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0266-9536\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"HENRY\";s:10:\"\u0000*\u0000aufirst\";s:4:\"S. P\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:11:\"MONTEITH, D\";i:1;s:10:\"BENNETT, F\";i:2;s:11:\"LEVIN, A. A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:131:\"Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-\u03b1 and C-raf kinase\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:131:\"Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-\u03b1 and C-raf kinase\";s:9:\"\u0000*\u0000jtitle\";s:23:\"Anti-cancer drug design\";s:9:\"\u0000*\u0000stitle\";s:21:\"Anti-cancer drug. des\";s:7:\"\u0000*\u0000date\";s:4:\"1997\";s:9:\"\u0000*\u0000volume\";s:2:\"12\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"409\";s:8:\"\u0000*\u0000epage\";s:3:\"420\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0266-9536\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"HENRY\";s:10:\"\u0000*\u0000aufirst\";s:4:\"S. P\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:11:\"MONTEITH, D\";i:1;s:10:\"BENNETT, F\";i:2;s:11:\"LEVIN, A. A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:131:\"Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-\u03b1 and C-raf kinase\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
